Cipla Ltd/India
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of CIPLA-NS would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (1996) — listing | $903,020 19.7× | $1,291,995 19.4× |
| Year 6 (2001) | $260,352 6.9× | $388,882 7.0× |
| Year 11 (2006) | $107,399 3.6× | $159,275 3.6× |
| Year 16 (2011) | $57,766 2.5× | $85,686 2.5× |
| Year 21 (2016) | $29,865 1.9× | $44,210 1.9× |
| Year 26 (2021) | $10,095 1.3× | $14,934 1.3× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Popular scenarios with CIPLA
For illustration only — not investment advice. Past performance is not indicative of future results.